As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Talphera, Inc. The largest reported stake is CorMedix Inc.'s, at 19.95%. 11 filings are on record since September 12, 2025 (Schedule 13D, September 12, 2025).
Sell to companies like Talphera, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Rosalind Advisors, Inc. · Sole voting: 0 · Shared voting: 12,913,182 · Sole dispositive: 0 · Shared dispositive: 12,913,182 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Lytton Laurence W · Percent: 2.5% · SCHEDULE 13G/A
- · Holder: Rosalind Advisors, Inc. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Lytton Laurence W · Percent: 5.9% · SCHEDULE 13G/A
- · Holder: Rosalind Advisors, Inc. · Percent: 9.9% · SCHEDULE 13G/A
Talphera, Inc. has 11 Schedule 13D or 13G filings on record since 2025-09-12. 4 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CorMedix Inc. | 19.95% | 9,090,909 | SCHEDULE 13D, 2025-09-12 | 2025-09-07 |
| Rosalind Advisors, Inc. | 9.9% | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| 9.8% | 4,661,502 | SCHEDULE 13G/A, 2026-01-30 | 2025-12-31 | |
| Rock Springs Capital Management LP | 7.88% | 3,589,186 | SCHEDULE 13G, 2025-09-12 | 2025-09-10 |
| 2.5% | 1,246,444 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Talphera, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Talphera, Inc. and the records around it.
Talphera, Inc. elsewhere on the record
- Form D filing Sep 2025
- Form D filing Apr 2025
- Who owns it
Companies that share a holder
- Rock Springs Capital Management LP also filed stake reports on 1 other company: Spruce Biosciences, Inc. (Aug 2025)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
- LYTTON LAURENCE W also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
Watch Talphera, Inc.
Get an email when Talphera, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Talphera, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Talphera, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Talphera, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 0 | 12,913,182 | 0 | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 |
| Salamon Steven A J | 0 | 12,913,182 | 0 | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 |
| Aharon Gil | 0 | 12,913,182 | 0 | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 |
| Rosalind Master Fund L.P. | 0 | 12,913,182 | 0 | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Talphera, Inc. by CUSIP 00444T209 and gives its principal executive office as 1850 GATEWAY DRIVE, SAN MATEO, CA 94404 (SCHEDULE 13G/A, 2026-08-12).
Purpose of Transaction (Item 4)
CorMedix Inc.
On September 7, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with the Reporting Person, pursuant to which the Reporting Person purchased from the Issuer in a private placement 9,090,909 Shares at a purchase price of $0.55 per share upon the First Closing (as defined in the Purchase Agreement). The First Closing occurred on September 10, 2025. Upon the First Closing, the Reporting Person has the right, subject to compliance with the applicable rules and regulations of The Nasdaq Capital Market, to designate one member of the Issuer's board of directors as long as the Reporting Person or its affiliates beneficially own at least 25% of the Shares the Reporting Person purchased at the First Closing. Additionally, pursuant to the Purchase Agreement, following the public announcement by the Issuer of the achievement of the primary endpoint and topline clinical data and results of the NEPHRO CRRT clinical study for the Issuer's product candidate Niyad (the "Public Announcement"), the Reporting Person shall have the right for 60 days thereafter (the "Exclusivity Period") to negotiate exclusively with the Issuer with respect to an acquisition of 100% of the capital stock and equity interests of the Issuer (the "Acquisition Transaction"). During the Exclusivity Period, the Issuer agreed that it shall not engage in discussions with any other third party about an Acquisition Transaction, a sale or exclusive license of all or substantially …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-12 | Rock Springs Capital Management LP | 7.88% | SCHEDULE 13G |
| 2025-09-12 | CorMedix Inc. | 19.95% | SCHEDULE 13D |
| 2025-09-16 | Lytton Laurence W | 8% | SCHEDULE 13G |
| 2025-11-10 | Orin Hirschman | 9.7% | SCHEDULE 13G |
| 2025-11-13 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-01-30 | Orin Hirschman | 9.8% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Lytton Laurence W | 5.9% | SCHEDULE 13G/A |
| 2026-05-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Lytton Laurence W | 2.5% | SCHEDULE 13G/A |
| 2026-08-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Talphera, Inc.
Who owns Talphera, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Talphera, Inc.: CorMedix Inc. (19.95%, Schedule 13D, filed 2025-09-12), Rosalind Advisors, Inc. (9.9%, Schedule 13G/A, filed 2026-08-12), Orin Hirschman (9.8%, Schedule 13G/A, filed 2026-01-30) and Rock Springs Capital Management LP (7.88%, Schedule 13G, filed 2025-09-12).
Who are the largest shareholders of Talphera, Inc.?
By the share each holder's latest filing reports, the largest holders of Talphera, Inc. on this page are CorMedix Inc. (19.95%), Rosalind Advisors, Inc. (9.9%) and Orin Hirschman (9.8%).
When did CorMedix Inc. buy into Talphera, Inc.?
The filings give report dates, not purchase dates. The earliest filing from CorMedix Inc. on this page is the Schedule 13D, filed 2025-09-12, reporting 19.95%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Talphera, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 15, 2025 | Form D, private offering | $16.98M sold | Form D page | Source |
| April 17, 2025 | Form D, private offering | $4.92M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Talphera, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.